Details:
The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Product Name: Sandostatin LAR Depot
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Aspen Pharmacare Holdings
Deal Size: $99.9 million Upfront Cash: Undisclosed
Deal Type: Agreement December 04, 2023
Details:
Under the terms of the agreement, Cipla will manufacture and market Galvus (vildagliptin) and Galvus combination brands, used in the treatment of type 2 diabetes.
Lead Product(s): Vildagliptin
Therapeutic Area: Endocrinology Product Name: Galvus
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cipla
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 11, 2023
Details:
Tirosint capsules is the leading branded gel capsule formulation of levothyroxine sodium in the US. It is formulated without excipients that can cause tolerability and drug absorption problems commonly observed with traditional levothyroxine tablet therapies.
Lead Product(s): Levothyroxine Sodium
Therapeutic Area: Endocrinology Product Name: Tirosint
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Mark Cuban Cost Plus Drug Company
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 07, 2023
Details:
Under the agreement, USV acquires the trademark for antidiabetes drug Jalra (vildagliptin) and Jalra M (vildagliptin and metformin), used to treat type 2 diabetes mellitus, from Novartis.
Lead Product(s): Vildagliptin
Therapeutic Area: Endocrinology Product Name: Jalra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: USV Private Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 22, 2021
Details:
The study examined the potency and consistency of Tirosint-SOL marketed by IBSA Pharma Inc, using the same methodology as the previous study to determine the degree to which the product maintains its labeled potency over a five-week period.
Lead Product(s): Levothyroxine Sodium
Therapeutic Area: Endocrinology Product Name: Tirosint-SOL
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2021